August 2015

Precision Oncology: Are Payers on the Right Pathway?

August 04, 2015

Evidence-Based Oncology

In oncology, the shift from a "companion diagnostic" to a "companion therapeutic" paradigm is in high gear. While the noise and confusion is leading many payers to avoid coverage, they can benefit by proactively taking steps to integrate precision oncology to better manage quality, access, and cost of cancer care.

Balancing Innovation With Cost in Diagnostic Testing

August 05, 2015

Evidence-Based Oncology

As clinical targets in more common malignancies emerge, testing and treatment options will increase. Balancing these choices with the high costs of new technology will be the challenge to ensure value in oncology care.

Equalize Payment Across Site of Service

August 10, 2015

Evidence-Based Oncology

For many US community cancer centers, keeping the doors open has often meant making the difficult decision to consolidate with hospitals and large hospital systems. Site neutrality is a critical step in the journey toward better healthcare for all Americans and a healthy future for Medicare.

Alternative Payment Models: Paving the Way or Building a Wall for Personalized Medicine?

August 07, 2015

Evidence-Based Oncology

As personalized medicine rapidly becomes an effective tool for combating cancer, payers are exploring new, value-based payment paradigms. These trends will soon intersect, and depending on how they are structured, the new payment models could accelerate or stifle personalized medicine's progress.

Personalized Medicine: On the Brink of Revolutionizing Cancer Care

August 10, 2015

Evidence-Based Oncology

With unprecedented activity in the area of precision medicine, with the successful development of several targeted therapies, the FDA has been in the forefront of efforts to ensure timely access to, and the safe and effective use of, these therapies.

The Need to Eliminate Barriers to Personalized Medicine

August 12, 2015

Evidence-Based Oncology

Precision medicine will perhaps establish some of the most important biomedical innovations of our generation. However, for that future to become a reality, we have to create an access and reimbursement environment that is conducive to precision care.

The Diagnosis for Diagnostics: Changes to Medicare Payment and Coverage of Clinical Laboratory Tests

August 13, 2015

Evidence-Based Oncology

The basis for determining Medicare payment rates for clinical diagnostic laboratory tests is changing. These changes will be important for all payers and providers to follow for future reimbursement and contract negotiations.

No Solution in Sight Yet With the Federal 340B Program, Say Stakeholders

August 13, 2015

Evidence-Based Oncology

A panel of healthcare experts invited by The American Journal of Managed Care participated in the Oncology Stakeholders Summit, Spring 2015 Peer Exchange, to discuss 340B and other issues in oncology care.

GAO: Congress Must End Incentives to Prescribe More Expensive Drugs Through 340B Program

August 14, 2015

Evidence-Based Oncology

A report from the Government Accountability Office has found that a program for hospitals serving poor and uninsured patients has created perverse incentives to prescribe more drugs and more expensive drugs, particularly in the area of cancer care.

CHAARTED Study: Conceptual Shift in Early Prostate Cancer Treatment

August 14, 2015

Evidence-Based Oncology

Analysis of results from the CHAARTED trial, published in the New England Journal of Medicine, has found that 6 cycles of chemotherapy (docetaxel) before androgen-deprivation therapy early in the treatment of metastatic prostate cancer significantly improved overall survival than treatment with ADT alone.